Strongbrigde Biopharma 200 Prozent Potential?

Ausgehend vom aktuell Kurs zum KZ von 21USD

http://www.finanzen.net/analyse/...y-Stifel_Nicolaus__Co__Inc__558835

Pipeline

http://www.strongbridgebio.com/pipeline/  

3,96

+0,54

+15,93 %  

http://www.finanzen.net/analyse/...rma_Buy-H_C_Wainwright__Co__600398  

könnte diesen Monat noch geschlossen werden

2,68 USD +0,23 USD +9,18 %  

http://www.nasdaq.com/de/symbol/sbbp/real-time  

Kann aber keine News finden! Das Kursziel ist aber sportlich :)

http://www.finanznachrichten.de/...ien/strongbridge-biopharma-plc.htm  

 

 

ist da was im Busch? Hört sich nicht viel an, aber sieht nach Umsatzrekord zumindest für dieses Jahr aus :)  

http://www.nasdaq.com/de/symbol/sbbp/real-time  

 

http://www.nasdaq.com/de/symbol/sbbp/real-time

 

http://www.finanzen.net/top50_ausland/  

http://seekingalpha.com/article/...37th-annual-health-care-conference  

aber es geht stetig aufwärts

4,10 USD +0,25 USD +6,49 %  

http://www.nasdaq.com/de/symbol/sbbp/real-time  

 

hereinflattern :)  

https://seekingalpha.com/article/...m-healthcare-conference-slideshow  

 

http://www.conferencecalltranscripts.org/8/summary/?id=4497144

~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~

~ MACRILEN is Strongbridge’s Second Commercial Product; Expands the Company’s Rare Endocrine Disease Portfolio and Complements its Late-Stage Clinical Development Program for RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome ~

~ Strongbridge Expands Structured Financing Facility with CRG to Support the Anticipated Commercial Launch of MACRILEN in Mid-2018 ~  

Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
GlobeNewswire•February 23, 2018

https://finance.yahoo.com/news/...plc-announces-annual-123000559.html

Annual General Meeting (AGM) of Shareholders on Tuesday, May 15, 2018 at the offices of Arthur Cox, Ten Earlsfort Terrace, Dublin, Ireland. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 28, 2018.  

http://www.analystratings.com/articles/...uy-rating-from-oppenheimer/  

http://www.analystratings.com/articles/...om-oppenheimer/#more-544448  

http://www.analystratings.com/articles/...strongbridge-biopharma-plc/